Latest Natalizumab Stories
Biopharma intelligence provider will also moderate live panel on funding biopharma innovation at Prix Galien USA on September 27 in NYC. Norwood, MA (PRWEB)
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001.
According to a new study, drugs used in the hope of slowing multiple sclerosis progression may come at a high cost for some patients who choose to use them.
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
LONDON and BRUSSELS, May 27, 2011 /PRNewswire/ -- UCB today announced data which showed that the addition of CimziaÂ® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.
BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research.
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed CimziaÂ®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA).
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology.
ALISO VIEJO, Calif., April 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In this newly created role, Mr.
EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc.
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.